Humanized anti-FGF19 antagonists and methods using same

A method for treating a cancer associated with expression and/or activity of FGF 19, the method comprising administering an effective amount of an anti-FGF19 antibody, comprising:

• (a) a light chain comprising:
• (i) hypervariable region (HVR)-L1 comprising sequence A1-A11, wherein A1-A11 is KASQDINSFLA (SEQ ID NO:
• 11);
• (ii) HVR-L2 comprising sequence B I-B7, wherein B1-B7 is RANRLVD (SEQ ID NO:2), RANRLVS (SEQ ID NO:
• 13), or RANRLVE (SEQ ID NO:
• 14);
• and (iii) HVR-L3 comprising sequence C1-C9, wherein C1-C9 is LQYDEFPLT (SEQ ID NO:3);
• and
• (b) a heavy chain comprising:
• (i) HVR-H1 comprising sequence D1-D10, wherein D1-D10 is GFSLTTYGVH (SEQ ID NO:4);
• (ii) HVR-H2 comprising sequence E1-E17, wherein E1-E17 is GVIWPGGGTDYNAAFIS (SEQ ID NO:7);
• and (iii) HVR-H3 comprising sequence F1-F13, wherein F1-F13 is VRKEYANLYAMDY (SEQ ID NO:8) to an individual in need of such treatment.